Atlas Venture Life Science Advisors LLC Has $141.58 Million Stock Position in Disc Medicine, Inc. $IRON

Atlas Venture Life Science Advisors LLC cut its stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 10.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,142,617 shares of the company’s stock after selling 241,839 shares during the period. Disc Medicine comprises approximately 18.8% of Atlas Venture Life Science Advisors LLC’s investment portfolio, making the stock its 2nd biggest position. Atlas Venture Life Science Advisors LLC owned approximately 6.16% of Disc Medicine worth $141,584,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd bought a new stake in Disc Medicine in the third quarter valued at $38,000. Avanza Fonder AB boosted its holdings in Disc Medicine by 54.0% during the 3rd quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock worth $110,000 after acquiring an additional 585 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in Disc Medicine by 8.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock valued at $133,000 after buying an additional 206 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Disc Medicine by 15,137.5% in the third quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company’s stock worth $161,000 after purchasing an additional 2,422 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Disc Medicine by 383.0% during the second quarter. Tower Research Capital LLC TRC now owns 3,975 shares of the company’s stock valued at $211,000 after buying an additional 3,152 shares during the period. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Disc Medicine Stock Up 0.5%

Shares of NASDAQ IRON opened at $60.04 on Friday. The stock has a market capitalization of $2.27 billion, a price-to-earnings ratio of -10.02 and a beta of 0.87. Disc Medicine, Inc. has a 12-month low of $30.82 and a 12-month high of $99.50. The firm’s 50-day moving average price is $71.11 and its 200-day moving average price is $75.62. The company has a current ratio of 21.94, a quick ratio of 21.94 and a debt-to-equity ratio of 0.04.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Thursday, February 26th. The company reported ($1.62) EPS for the quarter, topping analysts’ consensus estimates of ($1.69) by $0.07. The company had revenue of ($19.88) million during the quarter, compared to analysts’ expectations of $0.15 million. On average, equities research analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Wedbush cut their price target on Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a report on Tuesday, February 17th. Morgan Stanley set a $75.00 price objective on Disc Medicine in a research report on Tuesday, February 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Wednesday, January 21st. Stifel Nicolaus lowered their price target on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Finally, UBS Group reiterated an “overweight” rating on shares of Disc Medicine in a report on Thursday, January 15th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $104.80.

Insider Activity

In other news, CFO Jean M. Franchi sold 7,081 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $65.47, for a total transaction of $463,593.07. Following the transaction, the chief financial officer owned 71,343 shares of the company’s stock, valued at approximately $4,670,826.21. This represents a 9.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider William Jacob Savage sold 13,093 shares of Disc Medicine stock in a transaction on Monday, December 15th. The stock was sold at an average price of $91.22, for a total value of $1,194,343.46. Following the sale, the insider owned 75,702 shares of the company’s stock, valued at approximately $6,905,536.44. This trade represents a 14.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 206,985 shares of company stock valued at $17,497,533. 3.64% of the stock is currently owned by corporate insiders.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.